OAKLAND, CA., February 1, 2022 /PRNewswire/ — Ekoa digital health company advancing the detection of heart and lung disease, today announced that the Imperial College of Londonin collaboration with the National Health Service (NHS) of the United Kingdom, published a to study1 which highlights Eko’s ability to screen patients for heart failure in seconds with AI during physical exams.
Eko’s Low Ejection Fraction (ELEFT) algorithm detects a weakened heart pump, which is present in about half of patients with heart failure.2 It was developed in conjunction with the Mayo Clinic and will be submitted to the FDA under “Breakthrough Designation” for formal review later this year.
“This tool allows healthcare professionals to reliably confirm or rule out heart failure at the point of care,” said Dr. Nicholas Peters, Professor of Cardiology, Imperial College London. “The result will be earlier diagnosis and treatment and the avoidance of unnecessary and costly tests for those in whom heart failure is ruled out. This means better and more cost-effective health care. This is a complete game-changer.”
According to American Heart Associationan estimated 6 million American adults suffer from heart failure,3 with 26 million people affected worldwide.4 Diagnosis is a significant challenge since heart failure symptoms are also associated with many other conditions and detection often requires a series of expensive tests. By using the Eko DUO ECG + Digital Stethoscope with ELEFT, heart failure caused by a weakened heart pump can be detected within seconds during a stethoscope examination.
“The superhuman ability to screen patients at any point of care, including pre-surgery, should challenge the unacceptable reality that 80% of heart failure patients are currently diagnosed during an inpatient hospitalization. ’emergency,’ said Dr. Patrick Bachtiger, lead author and clinical researcher at the UK’s National Heart and Lung Institute. “The current clinical pathway is simply missing too many patients, leaving them undiagnosed until they are very sick. This tool can save time and money and unlock major patient benefits through early diagnosis and effective treatments.
In the study, the performance of the algorithm for detecting weak heart pump was excellent compared to the current gold standard of echocardiography. When 15-second recordings were made with the DUO at one location in the chest, the algorithm was 81% accurate in identifying normal and impaired heart pumping function. Accuracy increased to 86% when two save slots were used.
“This is a landmark study for several reasons,” said Dr. Adam Saltman, Chief Medical Officer at Eko. “The investigators have shown that the low ejection fraction detection algorithm can quickly, easily and effectively identify patients with impaired heart pumping function, even if these patients are not yet showing symptoms.”
Eko, a digital health company, is advancing the way healthcare professionals detect and monitor heart and lung disease through its innovative suite of digital tools, patient and provider software, and analytics based on the AI. Its FDA-approved platform is used by hundreds of thousands of healthcare professionals worldwide, enabling them to detect earlier and with greater accuracy, diagnose with more confidence, effectively manage the treatment and ultimately to give their patients the best possible care. Eko is headquartered in Oakland, Californiawith over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health and others. To learn more about Eko, visit ekohealth.com.
- Bachtiger, Patrik et al. Point-of-care screening for heart failure with reduced ejection fraction using artificial intelligence during an ECG-compatible stethoscope examination in London, UK: a prospective, observational, multicenter study. Lancet Digit Health, S2589-7500(21)00256-9. Jan 5, 2022doi:10.1016/S2589-7500(21)00256-9
- Borlaug, BA, & Redfield, MM (2011). Diastolic and systolic heart failure are distinct phenotypes in the spectrum of heart failure. Dissemination, 123(18), 2006–2014. https://doi.org/10.1161/CIRCULATIONAHA.110.954388
- Benjamin EJ, et al. Heart Disease and Stroke Statistics – 2018 Update: A Report from the American Heart Association. Broadcast, 2018;137(12):e67-e492
- Saravese G, et al. Global public health burden of heart failure. Card Fail Rev, 2017;3(1):7-11. doi: 10.15420/cfr.2016:25:2.